Show simple item record

A Genomic Signature of Influenza Infection Shows Potential for Presymptomatic Detection, Guiding Early Therapy, and Monitoring Clinical Responses.

dc.contributor.author Burke, T
dc.contributor.author Gilbert, A
dc.contributor.author Ginsburg, Geoffrey Steven
dc.contributor.author Hero, Alfred
dc.contributor.author Hudson, LL
dc.contributor.author Lambkin-Williams, R
dc.contributor.author Liu, TY
dc.contributor.author McClain, MT
dc.contributor.author Nichols, M
dc.contributor.author Nicholson, BP
dc.contributor.author Park, Lawrence P
dc.contributor.author Tsalik, Ephraim L
dc.contributor.author Veldman, T
dc.contributor.author Woods, Christopher Wildrick
dc.contributor.author Zaas, Aimee Kirsch
dc.coverage.spatial United States
dc.date.accessioned 2016-04-02T01:02:55Z
dc.date.issued 2016-01
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/26933666
dc.identifier ofw007
dc.identifier.uri http://hdl.handle.net/10161/11785
dc.description.abstract Early, presymptomatic intervention with oseltamivir (corresponding to the onset of a published host-based genomic signature of influenza infection) resulted in decreased overall influenza symptoms (aggregate symptom scores of 23.5 vs 46.3), more rapid resolution of clinical disease (20 hours earlier), reduced viral shedding (total median tissue culture infectious dose [TCID50] 7.4 vs 9.7), and significantly reduced expression of several inflammatory cytokines (interferon-γ, tumor necrosis factor-α, interleukin-6, and others). The host genomic response to influenza infection is robust and may provide the means for early detection, more timely therapeutic interventions, a meaningful reduction in clinical disease, and an effective molecular means to track response to therapy.
dc.language eng
dc.relation.ispartof Open Forum Infect Dis
dc.relation.isversionof 10.1093/ofid/ofw007
dc.subject gene expression
dc.subject genomic
dc.subject influenza
dc.subject oseltamivir
dc.title A Genomic Signature of Influenza Infection Shows Potential for Presymptomatic Detection, Guiding Early Therapy, and Monitoring Clinical Responses.
dc.type Journal article
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/26933666
pubs.begin-page ofw007
pubs.issue 1
pubs.organisational-group Basic Science Departments
pubs.organisational-group Biomedical Engineering
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Duke
pubs.organisational-group Duke Cancer Institute
pubs.organisational-group Global Health Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Institutes and Provost's Academic Units
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Cardiology
pubs.organisational-group Medicine, Infectious Diseases
pubs.organisational-group Molecular Genetics and Microbiology
pubs.organisational-group Pathology
pubs.organisational-group Pratt School of Engineering
pubs.organisational-group School of Medicine
pubs.organisational-group School of Nursing
pubs.organisational-group School of Nursing - Secondary Group
pubs.organisational-group University Institutes and Centers
pubs.publication-status Published online
pubs.volume 3


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record